BridgeBio to Host Limb-girdle Muscular Dystrophy Type 2I/R9 Investor Webinar on Friday, July 11th at 8:00 am ET

Core Insights - BridgeBio Pharma, Inc. is hosting an investor webinar on July 11, 2025, focusing on limb-girdle muscular dystrophy (LGMD) and its unmet needs [1][2] - Dr. Matthew Wicklund will present on LGMD, particularly LGMD2I/R9, and discuss the disease burden and standard of care [2] - The webinar will also cover the progress of BBP-418 and expectations for the Phase 3 interim analysis results in the second half of 2025 [3] Company Overview - BridgeBio Pharma is a biopharmaceutical company established to develop transformative medicines for genetic diseases, with a pipeline that includes early science to advanced clinical trials [5] - Founded in 2015, the company aims to leverage advances in genetic medicine to expedite patient treatment [5]